71 related articles for article (PubMed ID: 15790936)
1. Rho kinase inhibition and vascular protection: support from studies in Bartter and Gitelman syndrome.
Calò LA; Pagnin E; Davis PA; Sartori M; Semplicini A; Pessina AC
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):e34; author reply e34-5. PubMed ID: 15790936
[No Abstract] [Full Text] [Related]
2. Bartter's and Gitelman's syndromes: a confirm in humans of the utility of Rho kinase inhibition for cardiovascular protection.
Calò LA; Pagnin E; Sartori M; Semplicini A; Pessina AC
J Hypertens; 2005 Jun; 23(6):1273-5. PubMed ID: 15894907
[No Abstract] [Full Text] [Related]
3. Therapeutic potential of Rho-kinase inhibitors in asthma.
Xing XQ; Gan Y; Wu SJ; Chen P; Zhou R; Xiang XD
Med Hypotheses; 2007; 68(3):705-6. PubMed ID: 17055188
[No Abstract] [Full Text] [Related]
4. The role of Rho-associated kinase in differential regulation by statins of interleukin-1beta- and lipopolysaccharide-mediated nuclear factor kappaB activation and inducible nitric-oxide synthase gene expression in vascular smooth muscle cells.
Wei CY; Huang KC; Chou YH; Hsieh PF; Lin KH; Lin WW
Mol Pharmacol; 2006 Mar; 69(3):960-7. PubMed ID: 16317111
[TBL] [Abstract][Full Text] [Related]
5. Antagonistic modulation of vascular tone by Rho-kinase and nitric oxide: new insights into the mechanisms of blood pressure control.
Minuz P
J Hypertens; 2006 Jul; 24(7):1253-5. PubMed ID: 16794472
[No Abstract] [Full Text] [Related]
6. Rho/Rho-kinase and C-reactive protein relationship in hypertension and atherosclerosis.
Calò LA; Pagnin E; Mussap M; Davis PA; Semplicini A
Nephrol Dial Transplant; 2006 Apr; 21(4):1131-2. PubMed ID: 16287911
[No Abstract] [Full Text] [Related]
7. Adenovirus-mediated gene transfer into the brain stem to examine cardiovascular function: role of nitric oxide and Rho-kinase.
Hirooka Y
Prog Biophys Mol Biol; 2004; 84(2-3):233-49. PubMed ID: 14769438
[TBL] [Abstract][Full Text] [Related]
8. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery.
Shiga N; Hirano K; Hirano M; Nishimura J; Nawata H; Kanaide H
Circ Res; 2005 May; 96(9):1014-21. PubMed ID: 15817883
[TBL] [Abstract][Full Text] [Related]
9. Rho-kinase is an important therapeutic target in cardiovascular medicine.
Shimokawa H; Takeshita A
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1767-75. PubMed ID: 16002741
[TBL] [Abstract][Full Text] [Related]
10. Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells.
Sugimoto M; Nakayama M; Goto TM; Amano M; Komori K; Kaibuchi K
Biochem Biophys Res Commun; 2007 Sep; 361(2):462-7. PubMed ID: 17651694
[TBL] [Abstract][Full Text] [Related]
11. Rho kinase: a target for treating urinary bladder dysfunction?
Peters SL; Schmidt M; Michel MC
Trends Pharmacol Sci; 2006 Sep; 27(9):492-7. PubMed ID: 16870270
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways.
Nagaoka T; Hein TW; Yoshida A; Kuo L
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):825-32. PubMed ID: 17251484
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine-1-phosphate acts via rho-associated kinase and nitric oxide to regulate human placental vascular tone.
Hemmings DG; Hudson NK; Halliday D; O'Hara M; Baker PN; Davidge ST; Taggart MJ
Biol Reprod; 2006 Jan; 74(1):88-94. PubMed ID: 16162874
[TBL] [Abstract][Full Text] [Related]
14. Rho-kinase inhibitor may exert a role in preventing cardiac hypertrophy, independent of antihypertensive effects.
Pan M; Jing HM; Zhu JH; Liu ZH; Jiang WP; Yang XJ
Med Hypotheses; 2007; 68(1):234. PubMed ID: 16919397
[No Abstract] [Full Text] [Related]
15. Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells.
Itoh Y; Kimoto K; Imaizumi M; Nakatsuka K
Exp Eye Res; 2007 Mar; 84(3):464-72. PubMed ID: 17217948
[TBL] [Abstract][Full Text] [Related]
16. Expression and functional role of the RhoA/Rho-kinase pathway in rat coeliac artery.
Teixeira CE; Jin L; Ying Z; Palmer T; Priviero FB; Webb RC
Clin Exp Pharmacol Physiol; 2005 Oct; 32(10):817-24. PubMed ID: 16173942
[TBL] [Abstract][Full Text] [Related]
17. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease.
Budzyn K; Marley PD; Sobey CG
Trends Pharmacol Sci; 2006 Feb; 27(2):97-104. PubMed ID: 16376997
[TBL] [Abstract][Full Text] [Related]
18. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension.
Xing XQ; Gan Y; Wu SJ; Chen P; Zhou R; Xiang XD
Drug News Perspect; 2006 Nov; 19(9):517-22. PubMed ID: 17220956
[TBL] [Abstract][Full Text] [Related]
19. Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats.
Rajasekaran M; Wilkes N; Kuntz S; E Albo M
Neurourol Urodyn; 2005; 24(3):295-300. PubMed ID: 15791631
[TBL] [Abstract][Full Text] [Related]
20. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
